RT Journal Article
SR Electronic
T1 Incretin hypersecretion in gestational diabetes mellitus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.29.21266983
DO 10.1101/2021.11.29.21266983
A1 Louise Fritsche
A1 Martin Heni
A1 Sabine S. Eckstein
A1 Julia Hummel
A1 Anette Schürmann
A1 Hans-Ulrich Häring
A1 Hubert Preißl
A1 Andreas L. Birkenfeld
A1 Andreas Peter
A1 Andreas Fritsche
A1 Robert Wagner
YR 2021
UL http://medrxiv.org/content/early/2021/11/29/2021.11.29.21266983.abstract
AB Background Incretins are crucial stimulators of insulin secretion after food intake. We investigated the incretin response during an oral glucose tolerance test in pregnant women with and without gestational diabetes.Methods Subjects underwent a 5-point OGTT with 75 g glucose. We assessed insulin secretion and levels of total GLP-1, GIP, glicentin and glucagon during the OGTT.Findings We examined 167 women (33 with GDM) during gestational week 26.95 ±2.15. Insulin secretion was significantly lower in women with GDM (P<0.001). Postprandial GLP-1 and GIP were ∼20% higher in women with GDM (all P<0.05) independent from age, BMI and gestational age. GLP-1 increase associated with insulin secretion only in GDM, but not in NGT. Postprandial GLP-1 levels associated negatively with birth weight.Interpretation The more pronounced GLP-1 increase in women with GDM could be part of a compensatory mechanism counteracting GLP-1 resistance. Higher GLP-1 levels might be protective against fetal overgrowth.Funding This study was supported in part by a grant from the Federal Ministry of Education and Research (BMBF) (01GI0925) to the German Center for Diabetes Research (DZD).Competing Interest StatementRW reports lecture fees from NovoNordisk and travel grants from Eli Lilly. He served on the advisory board of Akcea Therapeutics. In addition to his current work, ALB reports lecture fees from Astra Zeneca, Boehringer Ingelheim, and NovoNordisk. He served on advisory boards of Astra Zeneca, Boehringer Ingelheim and NovoNordisk. Besides his current work, AF reports lecture fees and advisory board membership from Sanofi, Novo Nordisk, Eli Lilly, and AstraZeneca. In addition to is current work, MH reports research grants from Boehringer Ingelheim and Sanofi (both to the University Hospital of Tuebingen) and lecture fees from Sanofi, Novo Nordisk, Eli Lilly and Merck Sharp Dohme. None of the other authors report a conflict of interest directly related to the content of this work.Funding StatementThis study was supported in part by a grant from the Federal Ministry of Education and Research (BMBF) (01GI0925) to the German Center for Diabetes Research (DZD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics board of the University of Tuebingen gave ethical approval for this work (Protocal number 218/2012BO2, 06/15/2012)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll requests for data and materials will be promptly reviewed by the Data Access Steering Committee to verify whether the request is subject to any intellectual property or confidentiality obligations. Individual-level data may be subject to confidentiality. Any data and materials that can be shared will be released via a Material Transfer Agreement.AUCArea under the curveDPP-4Dipeptidyl Peptidase IVGDMGestational diabetes mellitusGIPGlucose dependent insulinotropic peptideGLP-1Glucagon like peptide-1GLP-1RGlucagon like peptide-1 receptorIGIInsulinogenic indexNEFA-ISINonesterified fatty acids - Insulin sensitivity indexNGTNormal glucose toleranceOGTTOral glucose tolerance test